YJYongxu Jia

Yongxu Jia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yongxu Jia has a total of 35 co-authors. Here are the top co-authors by number of shared publications:

  • Yanru Qin

    Department of Oncology, The First Affiliated Hospital of Zhengzhou University

    8 shared publications
  • Zehua Wang

    Department of Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou China

    7 shared publications
  • Lei Wang

    Department of Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou China

    5 shared publications
  • Wenjia Wang

    Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

    4 shared publications
  • Chen Chen

    Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

    3 shared publications
  • Jiayao Xu

    Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

    3 shared publications

Latest Publications

  • Open Access

    Efferocytosis: Signaling Pathways and New Therapeutic Strategies for Diseases

    by Lei Wang, Jingjing Ge, Zehua Wang, Yihua Fang, Yongxu Jia, Ruyue Zhang, Yanru Qin

    Efferocytosis—the phagocytic clearance of apoptotic cells (ACs)—is essential for maintaining tissue homeostasis, immune tolerance, and inflammation resolution. Beyond classic receptor‐mediated recognition, this process drives phagocyte metabolic reprogramming to actively facilitate tissue repair. Consequently, defective efferocytosis serves as a core pathogenic mechanism across major human diseases. This review outlines the molecular and metabolic foundations of efferocytosis and defines four universal hallmarks of its dysfunction: senescence‐driven impairment, unresolved inflammation, loss of immune tolerance, and fibrotic tissue repair. Subsequent sections explore how these defects manifest in cardiovascular, autoimmune, and neurodegenerative conditions, as well as cancer. Because efferocytosis exhibits a dual pathophysiological nature, therapeutic interventions must be highly disease‐specific. Enhancing apoptotic clearance can effectively resolve chronic inflammatory and fibrotic conditions. Conversely, because tumors hijack these same pathways to build immunosuppressive microenvironments, inhibiting efferocytosis remains a critical strategy in oncology. The synthesis of these divergent roles informs a “context‐dependent directionality” framework to guide the clinical translation of efferocytosis‐targeted precision therapies.


  • Open Access

    Correction: Co-occurrence patterns of esophageal and stomach cancer across 204 countries and territories: a spatial correspondence and systematic analysis

    by Jiayao Xu, Jiabei Gong, Huiqiong Han, Zehua Wang, Wenjia Wang, Lei Wang, Xin Sui, Guanyu Chen, Yongxu Jia, Yanru Qin

    Esophageal cancer (EC) and Stomach cancer (SC) are common malignant tumors of the digestive tract worldwide, posing a serious threat to human health (1)(2)(3). According to the latest global cancer statistics GLOBOCAN 2022, EC is the 11th most common cancer and the 7th leading cause of cancer death in the world, while SC is the 5th most common cancer and the 5th leading cause of cancer death in the world (4,5). Histologically, EC can be classified into two major subtypes: the disease burden of esophageal squamous cell carcinoma (ESCC) significantly exceeds that of esophageal adenocarcinoma (EAC) in most parts of the world (6). The vast majority of gastric cancers are histologically adenocarcinomas. The development of gastric cancer is closely associated with Helicobacter pylori infection (7). A meta-analysis and guidelines have indicated that H. pylori infection shows no association with ESCC, and may even be inversely associated with EAC (8,9). However, the esophagus and stomach are directly connected anatomically, particularly at the esophagogastric junction, where esophageal adenocarcinoma and gastric cardia cancer exhibit significant overlap in terms of pathogenesis, clinical presentation, and even molecular characteristics. Studies have shown that multiple environmental and behavioral risk factors contribute to the development of both cancers, including smoking, alcohol consumption, high salt intake, consumption of preserved foods, and low fruit and vegetable intake (10). It is worth noting that the burden of esophageal and gastric cancers varies considerably across regions. EC is highly prevalent in economically underdeveloped areas of Asia, Africa, and South America, where dietary habits are often poor. Meanwhile, SC incidence is particularly high in East Asia, Eastern Europe, and South America, regions characterized by lower economic development, unbalanced diets, and high rates of Helicobacter pylori infection (11). Therefore, a combined analysis facilitates a more comprehensive evaluation of their overall burden and its relationship with socioeconomic development.The GBD study is a comprehensive and systematic analysis of global health trends, offering critical insights into the incidence, prevalence, and mortality rates of various diseases (12,13).Previous studies have analyzed the disease burden and future trends of SC and EC in China based on GBD 2019 (14), but there are limitations such as insufficient data timeliness, limited to specific regions, lack of discussion on the impact of socio-economic development level, and no analysis of age-period-cohort factors and the impact of aging, epidemiological changes and population growth. Although numerous GBD-based studies on individual cancers exist (15)(16)(17)(18)(19), this is the first systematic comparative analysis of EC and SC, which are highly related in public health strategies, using GBD 2021 data. The study not only delineates the burden of each cancer but also emphasizes the similarities and differences in their spatial distribution of co-occurrence patterns, gender disparities, age distribution, and temporal trends. Furthermore, this research projects the disease burden of cancers over the next decade, which is critical for evaluating the impact of public health interventions and guiding strategic directions for future cancer control (20,21).The GBD 2021 is the most extensive and comprehensive epidemiological assessment of global disease burdens and trends to date. Disease and study population data were retrieved from the Global Burden of Disease 2021 database (https://ghdx.healthdata.org/gbd-2021). Esophageal cancer and Stomach cancer are defined using 150 and 151 in the International Classification of Diseases, ninth edition (ICD-9) code, and C15 and C16 in the tenth edition (ICD-10) revision code (2). To facilitate meaningful comparisons across different populations, age standardization was performed using the world standard population developed by Segi and modified by Doll et al (22,23). All estimates are presented as age-standardized rates (ASR). The SDI, which ranges from 0 to 1, was incorporated to examine the relationship between trends in esophageal and gastric cancers and socioeconomic development. Countries were also grouped into five SDI-based quintiles (following the classification scheme established by the Institute for Health Metrics and Evaluation). The SDI serves as a composite measure of national development, integrating total fertility rate, per capita income, and average educational attainment.In this study, we obtained and analyzed GBD 2021 data on gastric and esophageal cancers incidence, mortality and disability-adjusted life years (DALYs) by sex (male and female), age (20 age groups from 95 years, at 5-year intervals), SDI quintiles, 204 countries and territoriesTo investigate the co-occurrence patterns of EC and SC, as well as their spatial variations across different regions, incidence, mortality, and DALYs for both cancers in 2021 were classified into four tiers according to quartile ranges: low (75 percentile). Countries or territories where both cancers exhibited the same incidence level were categorized as consistent units; collectively, these constituted the consistent region. Those with a higher incidence level of EC relative to SC were identified as esophageal cancer-dominant units, forming the esophageal cancer-dominant region.Correspondingly, areas where stomach cancer incidence surpassed that of esophageal cancer were classified as stomach cancer-dominant units, aggregating into the stomach cancer-dominant region.Thus, the global study area was segmented into three distinct regions, each reflecting a distinct pattern of co-occurrence between EC and SC. Furthermore, Spearman rank correlation analysis was employed to quantify the bivariate association patterns. ASR were integrated and processed by "time-region type-metric type" with handling of missing values. The ranks of the...

  • Open Access

    Co-occurrence patterns of esophageal and stomach cancer across 204 countries and territories: a spatial correspondence and systematic analysis

    by Jiayao Xu, Jiabei Gong, Huiqiong Han, Zehua Wang, Wenjia Wang, Lei Wang, Xin Sui, Guanyu Chen, Yongxu Jia, Yanru Qin

    Background: Esophageal and gastric cancers are common malignant tumors of the digestive tract worldwide, characterized by a substantial disease burden and significant regional disparities. While these cancers share anatomical proximity, risk factors, and pathogenic mechanisms to some extent, there remains a lack of comprehensive and up-to-date global comparative studies on their co-occurrence patterns and burden trends. Methods: Using primary data from the Global Burden of Disease (GBD) 2021 study, we defined and categorized global co-occurrence patterns of esophageal and gastric cancers based on quartile methods. Descriptive analysis, correlation analysis, age-period-cohort modeling, decomposition analysis, and predictive modeling were employed to thoroughly examine the disease burden of both cancers across 204 countries and territories from 1990 to 2021. Results: The disease burden of gastric cancer consistently exceeded that of esophageal cancer in most countries and regions. Spatially, the Eastern and Northern Hemispheres, including countries such as China and Mongolia, were identified as consistent high-burden regions for both cancers. In contrast, the Western and Southern Hemispheres were predominantly characterized by single-cancer dominance or low-burden patterns. Disease burden was negatively correlated with the Socio-demographic Index (SDI), with higher burden observed in low-SDI regions. Males and older populations faced elevated disease risks. Furthermore, population growth and aging were identified as major drivers increasing the overall burden. Predictions indicate that by 2031, the age-standardized rates of both cancers will continue to decline, yet the overall burden of gastric cancer will remain significantly higher than that of esophageal cancer. Conclusions: Gastric cancer imposes a heavier disease burden than esophageal cancer across most countries and regions. These findings underscore the necessity for sustained and targeted prevention strategies, such as the promotion of healthy lifestyles, enhanced early screening, and improved healthcare accessibility in high-burden regions, to effectively reduce the global burden of esophageal and gastric cancers.


  • Open Access

    Pan-cancer analysis reveals MTTP as a prognostic and immunotherapeutic biomarker in human tumors

    by Wenjia Wang, Yaping Gao, Yihan Liu, Shurui Xia, Jiayao Xu, Liwei Qin, Yongxu Jia, Yanru Qin

    Introduction: Microsomal triglyceride transfer protein (MTTP) is an essential lipid transfer protein for the synthesis and secretion of very low density lipoprotein (VLDL) in hepatocytes and chylomicrons (CM) in intestinal cells. Further researches have revealed that MTTP exerted its functions in a variety of tissues beyond the liver and intestine, including the heart, neural tissues and antigen-presenting cells. Dysregulation of MTTP expression can lead to many diseases, such as lipid metabolism disorders, insulin resistance and cardiovascular diseases. Despite its importance, research on MTTP in cancer is limited, with no comprehensive pan-cancer studies available.Methods: MTTP expression was explored with the TIMER 2.0 and Sangerbox databases. The pathological stages and survival analysis of MTTP were analyzed via GEPIA and Kaplan Meier plotter. The gene mutations of MTTP were analyzed by cBioPortal database. The immune landscape of MTTP in the tumor microenvironment(TME) was analyzed using the TIMER 2.0 and single-cell sequencing. Based on the RNA-seq data in TCGA, we constructed GSEA enrichment analysis for MTTP. We identified the pro-tumor and anti-ferroptosis functions of MTTP in gastric cancer (GC) cells by in vitro and in vivo experiments, and analyzed the effect of TME on ferroptosis by single-cell sequencing.Results: MTTP expression was elevated in at least 1/3 tumors. High expression of MTTP was associated with poor prognosis in most tumors. MTTP levels were significantly correlated with three scores (immune, stromal, and extimate) and immune checkpoints in at least half of tumor types. Single cell sequencing of immune cells showed that MTTP was mainly expressed in macrophages, especially in microglia. MTTP increased in GC and MTTP knockdown limited the proliferation, migration and invasion abilities of GC cells, accompanied by increased sensitivity to ferroptosis. In addition, analyzing the ferroptosis genes associated with MTTP at the single cell level, we found that macrophages may be involved in the ferroptosis process in GC.Conclusions: Our pan-cancer study emphasizes that MTTP is a promising prognostic and immunotherapeutic biomarker in tumors. High expression of MTTP is correlated with the infiltration of diverse immune cells and regulates ferroptosis in GC cells, providing a potential target for tumor immunotherapy.


  • Open Access

    Single-cell N6-methyladenosine-related genes function within the tumor microenvironment to affect the prognosis and treatment sensitivity in patients with gastric cancer

    by Zehua Wang, Chen Chen, Jiao Shu, Jiaoyu Ai, Yihan Liu, Haoyue Cao, Yongxu Jia, Yanru Qin

    Background: Gastric cancer (GC) ranks fifth for morbidity and third for mortality worldwide. The N6-methyladenosine (m6A) mRNA methylation is crucial in cancer biology and progression. However, the relationship between m6A methylation and gastric tumor microenvironment (TME) remains to be elucidated. Methods: We combined single-cell and bulk transcriptome analyses to explore the roles of m6A-related genes (MRG) in gastric TME. Results: Nine TME cell subtypes were identified from 23 samples. Fibroblasts were further grouped into four subclusters according to different cell markers. M6A-mediated fibroblasts may guide extensive intracellular communications in the gastric TME. The m6A-related genes score (MRGs) was output based on six differentially expressed single-cell m6A-related genes (SCMRDEGs), including GHRL, COL4A1, CAV1, GJA1, TIMP1, and IGFBP3. The protein expression level was assessed by immunohistochemistry. We identified the prognostic value of MRGs and constructed a nomogram model to predict GC patients’ overall survival. MRGs may affect treatment sensitivity in GC patients. Conclusion: Our study visualized the cellular heterogeneity of TME at the single-cell level, revealed the association between m6A mRNA modification and intracellular communication, clarified MRGs as an independent risk factor of prognosis, and provided a reference for follow-up treatment.


  • Open Access

    Chimeric antigen receptor T-cell therapy for multiple myeloma

    by Zehua Wang, Chen Chen, Lei Wang, Yongxu Jia, Yanru Qin

    Multiple myeloma (MM) is a malignant plasma cell disorder that remains incurable for most patients, as persistent clonal evolution drives new mutations which confer MM high-risk signatures and resistance to standard care. The past two decades have significantly refashioned the therapeutic options for MM, especially adoptive T cell therapy contributing to impressive response rate and clinical efficacy. Despite great promises achieved from chimeric antigen receptor T-cell (CAR-T) therapy, the poor durability and severe toxicity (cytokine release syndrome and neurotoxicity) are still huge challenges. Therefore, relapsed/refractory multiple myeloma (RRMM), characterized by the nature of clinicopathologic and molecular heterogeneity, is frequently associated with poor prognosis. B Cell Maturation Antigen (BCMA) is the most successful target for CAR-T therapy, and other potential targets either for single-target or dual-target CAR-T are actively being studied in numerous clinical trials. Moreover, mechanisms driving resistance or relapse after CAR-T therapy remain uncharacterized, which might refer to T-cell clearance, antigen escape, and immunosuppressive tumor microenvironment. Engineering CAR T-cell to improve both efficacy and safety continues to be a promising area for investigation. In this review, we aim to describe novel tumor-associated neoantigens for MM, summarize the data from current MM CAR-T clinical trials, introduce the mechanism of disease resistance/relapse after CAR-T infusion, highlight innovations capable of enhanced efficacy and reduced toxicity, and provide potential directions to optimize manufacturing processes.


  • Open Access

    Predictive significance of STK17A in patients with gastric cancer and association with gastric cancer cell proliferation and migration

    by Zehua Wang, Chenyi Wang, Bing-Hua Jiang, Litong Shi, Shan Lin, Lei Wang, Ling-Zhi Liu, Jian-Ge Qiu, Yanru Qin, Yongxu Jia

    Gastric cancer (GC) is one of the most frequently diagnosed types of cancer worldwide, and exploring its potential therapeutic targets is particularly important for improving the prognosis of patients with GC. The aim of the present study was to investigate the association between serine/threonine kinase 17a (STK17A) expression and GC prognosis. STK17A expression was measured by quantitative real‑time PCR, western blotting and immunohistochemical staining. Standard stable transfection technology was also used to construct overexpression and knockdown cell lines. Wound healing, Transwell, Cell Counting Kit‑8 and colony formation assays, as well as other methods, were used to explore the function and underlying molecular mechanism of STK17A in GC. The results indicated that STK17A overexpression significantly promoted the proliferation and migration of GC cells. The clinical significance of STK17A in a cohort of 102 cases of GC was assessed by clinical correlation and Kaplan‑Meier analyses. Overexpression of STK17A was demonstrated to be associated with tumor invasion depth (P<0.001), lymph node metastasis (P<0.001) and poor prognosis in terms of 5‑year survival (P<0.001). In addition, Cox multivariate analysis revealed that STK17A expression was an independent risk factor for overall and progress‑free survival (P<0.001). Therefore, STK17A may be a valuable biomarker for the prognosis of patients with GC.


  • Over-expression of S100B protein as a serum marker of brain metastasis in non-small cell lung cancer and its prognostic value

    by Lijuan Chen, Xiufeng Hu, Huijuan Wu, Yongxu Jia, Jie Liu, Xiaoqian Mu, Hongbo Wu, Yanqiu Zhao